Non-alcoholic Steatohepatitis Market Global Outlook and Forecast 2025-2032

The global Non-alcoholic Steatohepatitis market size was estimated at USD 2532 million in 2024 and is projected to reach USD 13664.37 million by 2032, exhibiting a CAGR of 20.60% during the forecast period.

North America Non-alcoholic Steatohepatitis market size was estimated at USD 913.33 million in 2024, at a CAGR of 17.66% during the forecast period of 2025 through 2032. 

Report Overview

Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver.

Key Company

• AstraZeneca

• Pfizer

• GSK

• Novo Nordisk

• Roche

• AbbVie

• Galectin Therapeutics

• Galmed Pharmaceuticals

• Gilead

• Intercept pharma

• Non-alcoholic Steatohepatitis

• Takeda

Market Segmentation (by Type)

• Solid

• Liquid

Market Segmentation (by Application)

• Oral

• Parenteral

Get free sample of this report at : https://www.24marketresearch.com/download-free-sample/8027555/global-nonalcoholic-steatohepatitis-2025-2032-296